



NEPHRO CARE INDIA LIMITED
(FORMERLY KNOWN AS NEPHRO CARE INDIA PRIVATE LIMITED)
CIN:U85100WB2014PLC202429
Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake, Bidhan Nagar,
Sai Complex, North 24 Parganas, Kolkata - 700106, West Bengal, India.
Web: <https://www.nephrocareindia.com/>

Date: 20th August 2024

The Manager,
Listing Department National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051, Maharashtra, India.

Symbol: NEPHROCARE

Sub: Outcome of the Board Meeting dated 20th August 2024

Ref: **Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sirs,

Pursuant to Regulation 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that the Board of Directors of the Company at its meeting held today 20th August, 2024, (commenced at 1730 Hours and concluded at 1900 Hours) interalia, approved the following;

Pursuant to the provisions of Regulation 33 of the Listing Regulations, we enclose the following:

1. Audited Financial Results of the Company for the financial year ended 31st March 2024 along with Cash Flows Statement for the financial year ended on that date and Statement of Assets and Liabilities as on that date;
2. Auditors' Report on the Audited Financial Results of the Company for the financial year ended 31st March 2024; and
3. Declaration in respect of Audit Report with Unmodified Opinion on the Financial Results of the Company for the financial year ended 31st March 2024.

The Board meeting commenced at 1730 Hours (IST) and concluded at 1900 Hours (IST).



NEPHRO CARE INDIA LIMITED
(FORMERLY KNOWN AS NEPHRO CARE INDIA PRIVATE LIMITED)
CIN:U85100WB2014PLC202429
Regd. Office- Flat No-1, JC-18, 5th Floor Sec-III, Saltlake, Bidhan Nagar,
Sai Complex, North 24 Parganas, Kolkata - 700106, West Bengal, India.
Web: <https://www.nephrocareindia.com/>

The above announcements are also being made available on the website of the Company at www.nephrocareindia.com. This disclosure is made in compliance with Regulation 30 read with Regulation 51 and 52 of SEBI LODR, as amended.

This is for your information and records.

For, **Nephro Care India Limited**

SOUGATA Digitally signed by
SOUGATA SENGUPTA
SENGUPTA Date: 2024.08.20
17:21:49 +05'30'

Sougata Sengupta
Company Secretary



K. K. Chanani & Associates

Chartered Accountants

An ISO 9001:2008 Certified Firm, Certificate No.: 221010128008

Head Office: 5/1 Clive Row, 3rd Floor, Room No.78, Kolkata-700001

Branches: Bangalore, Guwahati, Jaipur, Mumbai, New Delhi, Patna,
Nashik, Raipur and Ranchi.

Contact: Dial: +91 9830044507, +9133- 22130296

Email: kkca@kkca.net.

INDEPENDENT AUDITOR'S REPORT ON THE AUDITED FINANCIAL RESULTS OF NEPHRO CARE INDIA LIMITED (FORMERLY CALLED NEPHRO CARE INDIA PRIVATE LIMITED) FOR THE YEAR ENDED 31 MARCH 2024 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 AS AMENDED

To
The Board of Directors
Nephro Care India Limited

OPINION

We have audited the accompanying financial results of **M/S NEPHRO CARE INDIA LIMITED** (the company) for the year ended 31 March 2024 ("the Statement") herewith being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement: -

- i. is presented in accordance with the requirements of the Listing Regulations in this regard; and
- ii. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable accounting standards and other accounting principles generally accepted in India, of its profit and other financial information of the Company for the year ended 31 March 2024.

BASIS FOR OPINION

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013 (the Act). Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



MANAGEMENT'S RESPONSIBILITIES FOR THE FINANCIAL RESULTS

The Statement has been prepared on the basis of the financial statements for the year ended 31 March 2024. The Company's Board of Directors are responsible for the preparation of these financial results that give a true and fair view of its profit of the Company and other financial information in accordance with the applicable accounting standards prescribed under section 133 of the Act read with relevant rules issued under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations.

This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error. In preparing the financial results, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. The Board of Directors are also responsible for overseeing the Company's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL RESULTS

Our objectives are to obtain reasonable assurance about whether the financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit.

We also:

- Identify and assess the risks of material misstatement of the financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.



- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial results, including the disclosures, and whether the financial results represent the underlying transactions and events in a manner that achieves fair presentation.
- We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The company was listed in SME Platform in NSE Emerge on 5th July, 2024 and thus half yearly figures for the period ended 31st March 2023, September 2023 and 31 March 2024 are not provided, hence no half year figures were drawn or separately reviewed by the Board


Krishna Kumar Chanani
Partner, K K Chanani & Associates
Chartered Accountants
Membership No. 056045
FRN No. 322232E
UDIN No. 24056045BKBIIY3213



Kolkata, the 20th August, 2024

Nephro Care India Limited
(Formerly called Nephro Care India Private Limited)
CIN:U85100WB2014PLC202429
Statement of Audited Assets and Liabilities as at 31 March 2024

(All amounts in ₹ lacs , unless otherwise stated)

	As at 31 March 2024	As at 31 March 2023
Equity and liabilities		
Shareholders' funds		
Share capital	1,190.24	50.00
Reserves and surplus	312.29	202.87
	1,502.53	252.87
Non-Current liabilities		
Long-term borrowings	-	243.85
Long-term provisions	7.76	-
	7.76	243.85
Current liabilities		
Short -term borrowings	-	4.30
Trade Payables		
- total outstanding dues of micro enterprises and small enterprises	-	-
- total outstanding dues of creditors other than micro and small enterprises	187.41	93.86
Other current liabilities	219.25	152.72
Short-term provisions	179.77	78.28
	586.43	329.16
Total	2,096.72	825.88
Assets		
Non-Current Assets		
Property, Plant and Equipment and Intangible Assets		
(i) Property, Plant and Equipment	473.50	301.27
(ii) Capital work-in-progress	85.76	-
Non-current investments	650.98	200.00
Deferred Tax Assets (net)	8.47	9.23
Long term loans and advances	305.78	-
Other non-current assets	132.65	21.01
	1,657.14	531.51
Current assets		
Inventories	35.21	48.43
Trade Receivables	15.41	4.34
Cash and cash equivalents	129.06	231.66
Short term loans and advances	9.96	0.22
Other current assets	249.94	9.72
	439.58	294.37
Total	2,096.72	825.88

Place: Kolkata
Date: 20 Day of August 2024



For and on behalf of the Board of Directors of

Nephro Care India Limited

Pratim Sengupta

Pratim Sengupta
Managing Director
(DIN: 03501703)

Tapas Saha

Tapas Saha
(Chief Financial Officer)
(PAN:BNSPS8900F)

SOUGATA SENGUPTA

Digitally signed by
SOUGATA SENGUPTA
Date: 2024.08.20
20:34:42 +05'30'

Nephro Care India Limited
 (formerly called Nephro Care India Private Limited)
 CIN:U85100WB2014PLC202429
 Statement of Audited Financial Results for the year ended 31 March 2024

(All amounts in ₹ lacs , unless otherwise stated)

	Year ended 31 March 2024	Year ended 31 March 2023
Revenue from operations	2,723.08	1,709.27
Other income	37.00	0.21
Total Income	2,760.08	1,709.48
Expenses		
Changes in inventory of pharmacy, drugs and consumables	13.22	(31.37)
Purchases of pharmacy, drugs and	895.24	527.79
Employee Benefit Expenses	215.76	111.35
Finance Cost	8.51	6.57
Depreciation and Amortisation	52.76	78.43
Other expenses	952.25	758.99
Total expenses	2,137.74	1,451.76
Profit/(loss) before tax	622.34	257.72
Tax expense		
Current tax	163.00	78.28
Tax Expenses of prior years	8.73	-
Deferred Tax	0.37	(57.81)
	172.10	20.47
Profit/(loss) for the year before prior period adjustments	450.24	237.25
Add: Prior Period Adjustments (net)	(9.10)	-
Profit/(loss) for the year after prior period adjustments	441.14	237.25
Earnings per equity share		
Basic and diluted	3.80	2.37

Note:-

- 1) The above financial statements were approved by Audit Committee approved by Board of Directors on dated 20-08-2024
- 2) The compliance of IND-AS is not applicable as company is listed on SME Platform on NSE Emerge
- 3) The company was listed in SME Platform on NSE Emerge on 5th July, 2024 and thus half yearly figures for the period ended 31st March 2023 and September 2023 are not provided, hence no half year figures was drawn or separately reviewed by the Board
- 4) Figures for the previous year have been regrouped and reclassified to conform to classification of the current period wherever necessary

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Pratim Sengupta
 Managing Director
 (DIN: 03501703)

Tapas Saha
Tapas Saha
 (Chief Financial Officer)
 (PAN:BNSPS8900F)

Place: Kolkata
 Date: 20 Day of August 2024



**SOUGATA
 SENGUPTA**

Digitally signed by
 SOUGATA SENGUPTA
 Date: 2024.08.20 20:36:07
 +05'30'

(All amounts in ₹ lacs , unless otherwise stated)

	Year ended 31 March 2024	Year ended 31 March 2023
A. Cash flow from operating activities :		
Profit before tax	622.34	257.72
Adjustment for :		
Depreciation	52.76	78.43
Interest Income from Fixed Deposit	(0.91)	(0.09)
Profit from sale of investments	(26.05)	-
Interest on loan	0.13	0.80
Operating profit before working capital changes	648.27	336.86
Adjustments for changes in working capital:		
(Increase) / decrease in assets:		
Inventories	13.22	(31.37)
Trade Receivables	(11.07)	15.09
Other current assets	(71.74)	4.30
Short-term loans and advances	(9.74)	(0.01)
Long-term loans and advances	(305.78)	-
Other non-current assets	(111.64)	-
Increase / (decrease) in liabilities:		
Trade Payables	93.55	(46.59)
Long-term provisions	7.76	-
Short-term provisions	0.33	-
Other current liabilities	67.44	138.19
Cash generated from operations	320.60	416.47
Income taxes paid (net of refunds)	(229.52)	(4.28)
Net cash generated from operating activities (A)	91.08	412.19
B. Cash flow from investing activities		
Purchase of Property, Plant and Equipment	(243.16)	(50.48)
Capital work-in-progress	(85.76)	-
Proceeds from Fixed Deposits	-	17.11
Redemption of Mutual Fund	550.00	(200.00)
Investment in Mutual Funds	(975.00)	0.09
Interest Income from Fixed Deposits	-	-
Net cash used in investing activities (B)	(753.92)	(233.28)
C. Cash flow from financing activities		
Proceeds/(Repayment) from Borrowings	(248.15)	(7.35)
Increase in Share Capital	9.51	-
Securities Premium Received	799.01	-
Interest paid	(0.13)	(0.80)
Net cash used in financing activities (C)	560.24	(8.15)
Net increase in cash and cash equivalents (A+B+C)	(102.60)	170.76
Cash and cash equivalents as at the beginning of the year	231.66	60.90
Cash and cash equivalents as at the end of the year	129.06	231.66
Note:		
Cash and bank balances	129.06	231.66
Less: Other bank balances	-	-
Cash and cash equivalents	129.06	231.66

The statement of cashflow has been prepared under the indirect method as set out in Accounting Standard 3 on Cash Flow Statement as specified under Section 133 of the Companies Act 2013 read with Companies (Accounting Standards) Rules, 2021

For and on behalf of the Board of Directors of
Nephro Care India Limited

Pratim Sengupta
Pratim Sengupta
 Managing Director
 (DIN: 03501703)

Tapas Saha
Tapas Saha
 (Chief Financial Officer)
 (PAN: BNSPS8900F)



Place: Kolkata

Date: 20 Day of August 2024

SOUGATA SENGUPTA
 Digitally signed by
 SOUGATA SENGUPTA
 Date: 2024.08.20
 20:36:54 +05'30'